Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO

Authors :: Antoniotti, C.
Cremolini, C.
Loupakis, F.
Francesca Bergamo
Grande, R.
Tonini, G.
Silvio, K. Garattini
Masi, G.
Battaglin, F.
Lucchesi, S.
Salvatore, L.
Corsi, D.
Di Fabio, F.
Banzi, M.
Moretto, R.
Sensi, E.
Rossini, D.
Tomcikova, D.
Fontanini, G.
Zagonel, V.
Boni, L.
Falcone, A.
Source :: Publons, ResearcherID

Tools